We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Communication |

Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children

Tracy A. Lieu, MD, MPH; G. Thomas Ray, MBA; Steven B. Black, MD; Jay C. Butler, MD; Jerome O. Klein, MD; Robert F. Breiman, MD; Mark A. Miller, MD; Henry R. Shinefield, MD
JAMA. 2000;283(11):1460-1468. doi:10.1001/jama.283.11.1460.
Text Size: A A A
Published online

Context Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media.

Objective To evaluate the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children.

Design Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomized trial and other published and unpublished sources.

Setting and Patients A hypothetical US birth cohort of 3.8 million infants.

Interventions Hypothetical comparisons of routine vaccination of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 months), and catch-up vaccination of children aged 2 to 4.9 years requiring 1 dose, with children receiving no intervention.

Main Outcome Measures Cost per life-year saved and cost per episode of meningitis, bacteremia, pneumonia, and otitis media prevented.

Results Vaccination of healthy infants would prevent more than 12,000 cases of meningitis and bacteremia, 53,000 cases of pneumonia, 1 million episodes of otitis media, and 116 deaths due to pneumococcal infection. Before accounting for vaccine costs, the vaccination program would save $342 million in medical and $415 million in work-loss and other costs from averted pneumococcal disease. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose. At the manufacturer's list price of $58 per dose, infant vaccination would cost society $80,000 per life-year saved or $160 per otitis media episode prevented (other estimated costs would be $3200 per pneumonia case prevented, $15,000 for bacteremia, and $280,000 for meningitis). The cost-effectiveness of an additional program to administer 1 dose of vaccine to children aged 2 to 4.9 years would vary depending on the children's ages, relative risks of pneumococcal disease, and vaccine cost.

Conclusions Pneumococcal conjugate vaccination of healthy US infants has the potential to be cost-effective. To achieve cost savings, its cost would need to be lower than the manufacturer's list price. In addition to tangible costs, the vaccine should be appraised based on the less tangible value of preventing mortality and morbidity from pneumococcal disease.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Figure 1. Policy Options and Clinical Outcomes After No Vaccination or Vaccination of All Healthy Infants With Pneumococcal Conjugate Vaccine
Graphic Jump Location
Dashed lines denote outcomes for which incidence estimates are used; these outcomes are not mutually exclusive. Node 2 is identical in structure to node 1, but disease incidence is reduced due to vaccination.
Figure 2. Projected Cost per Life-Year Saved and Cost per Otitis Media Episode Prevented by Routine Pneumococcal Conjugate Vaccination of Healthy US Infants, at Varying Vaccine Cost per Dose
Graphic Jump Location
Four doses would be recommended for infant vaccination. Cost-effectiveness analysis from the societal perspective includes medical and nonmedical costs; cost-effectiveness analysis from the health care payer perspective includes medical costs primarily borne by health plans.
Figure 3. Two-Way Sensitivity Analysis That Illustrates How the Break-Even Vaccine Cost for Children Aged 2 to 4.9 Years Varies Depending on the Relative Risk of Disease
Graphic Jump Location
The lines represent the break-even vaccine costs at varying relative risks of disease from the societal perspective (medical and nonmedical costs) and health care payer perspective (medical costs). For costs and relative risks below each line, vaccination would result in net savings. Above each line, vaccination would result in net costs. Children in day care have a relative risk of 2.4 compared with those not in day care.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

194 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles